The PSNC has announced a number of changes to Part VIIIB in February’s Drug Tariff, including amended minimum pack size volumes, price changes, and the deletion of the following two products: 
 

• Ramipril 2.5mg/5ml oral solution (a newly licensed Ramipril 2.5mg/5ml oral solution preparation is now available, manufactured by Rosemont Pharmaceuticals; as such this listing will be moved to Part VIIIA)

• Clobazam 5mg/5ml and 10mg/5ml oral solution (clobazam liquid can only be manufactured as an oral suspension; as such, the listings for Clobazam oral solutions have been removed)

Please see the link below for further information.